Molecular basis of a dominant T cell response to an HIV reverse transcriptase 8-mer epitope presented by the protective allele HLA-B*51:01 by Motozono, Chihiro et al.
of March 10, 2014.
This information is current as
Allele HLA-B*51:01
8-mer Epitope Presented by the Protective
Response to an HIV Reverse Transcriptase 
Molecular Basis of a Dominant T Cell
Andrew K. Sewell and Masafumi Takiguchi
Rizkallah, Anna Fuller, Shinichi Oka, David K. Cole, 
Chihiro Motozono, Nozomi Kuse, Xiaoming Sun, Pierre J.
ol.1302667
http://www.jimmunol.org/content/early/2014/03/05/jimmun
 published online 5 March 2014J Immunol 
Material
Supplementary
7.DCSupplemental.html
http://www.jimmunol.org/content/suppl/2014/03/05/jimmunol.130266
Subscriptions
http://jimmunol.org/subscriptions
 is online at: The Journal of ImmunologyInformation about subscribing to 
Permissions
http://www.aai.org/ji/copyright.html
Submit copyright permission requests at: 
Email Alerts
http://jimmunol.org/cgi/alerts/etoc
Receive free email-alerts when new articles cite this article. Sign up at: 
Print ISSN: 0022-1767 Online ISSN: 1550-6606. 
Copyright © 2014 The Authors All rights reserved.
9650 Rockville Pike, Bethesda, MD 20814-3994.
The American Association of Immunologists, Inc.,
 is published twice each month byThe Journal of Immunology
 at Cardiff U
niv on M
arch 10, 2014
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
 at Cardiff U
niv on M
arch 10, 2014
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
The Journal of Immunology
Molecular Basis of a Dominant T Cell Response to an HIV
Reverse Transcriptase 8-mer Epitope Presented by the
Protective Allele HLA-B*51:01
Chihiro Motozono,*,1 Nozomi Kuse,†,1 Xiaoming Sun,† Pierre J. Rizkallah,*
Anna Fuller,* Shinichi Oka,†,‡ David K. Cole,*,2 Andrew K. Sewell,*,2 and
Masafumi Takiguchi†,2
CD8+ CTL responses directed toward the HLA-B*51:01–restricted HIV-RT128–135 epitope TAFTIPSI (TI8) are associated with
long-term nonprogression to AIDS. Clonotypic analysis of responses to B51-TI8 revealed a public clonotype using TRAV17/
TRBV7-3 TCR genes in six out of seven HLA-B*51:01+ patients. Structural analysis of a TRAV17/TRBV7-3 TCR in complex
with HLA–B51-TI8, to our knowledge the first human TCR complexed with an 8-mer peptide, explained this bias, as the unique
combination of residues encoded by these genes was central to the interaction. The relatively featureless peptide-MHC (pMHC)
was mainly recognized by the TCR CDR1 and CDR2 loops in an MHC-centric manner. A highly conserved residue Arg97 in the
CDR3a loop played a major role in recognition of peptide and MHC to form a stabilizing ball-and-socket interaction with the
MHC and peptide, contributing to the selection of the public TCR clonotype. Surface plasmon resonance equilibrium binding
analysis showed the low affinity of this public TCR is in accordance with the only other 8-mer interaction studied to date (murine
2C TCR–H-2Kb-dEV8). Like pMHC class II complexes, 8-mer peptides do not protrude out the MHC class I binding groove like
those of longer peptides. The accumulated evidence suggests that weak affinity might be a common characteristic of TCR binding
to featureless pMHC landscapes. The Journal of Immunology, 2014, 192: 000–000.
T
he cytotoxic payload delivered by CD8+ CTLs destroys
cells posing a threat to host health. To ensure that this
cytotoxicity is specifically targeted toward aberrant cells,
CTLs express a TCR that can distinguish between self- and non–
self-peptides (usually ranging from 8–13 aa) presented on the
surface of most nucleated cells in peptide–MHC class I (pMHCI)
(1, 2). Thus, T cells have the ability to scan the cellular proteome
via the cell surface, providing an important mechanism for tar-
geting diseased cells. CTLs constitute our main defense against
intracellular infections and can destroy virally infected cells. It is
well established that certain HLA molecules, such as HLA-B*27,
HLA-B*51, and HLA-B*57, are associated with better control of
HIV infection (3–5). These findings attest to the importance of
CD8+ CTL responses in HIV infection and have generated con-
siderable interest in the mechanisms behind this protection in
HIV-1–infected individuals carrying these HLA alleles. In this
study, we focused on the response to HLA-B*51:01–restricted
HIV-RT128–135 8-mer epitope (TAFTIPSI [TI8]). HLA-B*51:01 is
associated with slow progression to AIDS, and B51-TI8–specific
T cells strongly suppress HIV-1 replication in vitro (6). Further-
more, the magnitude of the B51-TI8–specific CD8+ T cell re-
sponse was significantly correlated to low plasma viral load in
chronically HIV-1–infected HLA-B*51:01+ Japanese hemophil-
iacs, whereas no correlation was found between the magnitude of
the CD8+ T cell response to three other dominant HLA-B51–re-
stricted HIV-1 epitopes (7). Collectively, these correlative data
suggest that the response to B51-TI8–specific CD8+ T cells might
play an important role in the control of HIV-1 replication.
We undertook to dissect HLA-B*51:01–restricted CTL re-
sponses to this important epitope by examining the TCRs raised
against the B51-TI8 epitope in responding patients. We identified
a public CTL clone (3B) expressing a TCR encoded by TRAV17/
TRBV7-3 TCR genes, specific for B51-TI8. We solved the
structure of the 3B TCR in complex B51-TI8 and conducted
a biophysical analysis of the interaction. To our knowledge, the
3B–B51-TI8 structure is the first human TCR complex with HLA-
B*51:01 and the first containing a short 8-mer peptide without
a prominent central bulge. Our data reveal the genetic and mo-
lecular mechanism explaining the predominance of TRAV17/
TRBV7-3 TCRs in HLA-B*51:01+ HIV+ patients and provide
new structural insights into CTL recognition of a flat 8-mer pep-
tide presented by HLA-B*51:01.
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Materials and Methods
Patients
Seven chronically HIV-1–infected Japanese individuals were recruited for the
current study, which was approved by the ethics committees of Kumamoto
University and the National Center for Global Health and Medicine, Japan.
Written informed consent was obtained from all subjects according to the
Declaration of Helsinki. We focused on seven HLA-B*51:01+ Japanese
individuals chronically infected with HIV-1 because HLA-B*51:01–re-
stricted TI8-specific CTLs were induced by stimulating PBMCs from only
these individuals with TI8 peptides. Three individuals (KI-021, KI-051, and
KI-124) are hemophiliacs and long-term nonprogressors. Clinical records
and HLA type of these individuals are shown in Supplemental Table I.
Generation of TI8-specific CTLs
HLA-B*51:01–restricted TI8-specific CTL clones were generated from
HIV-1–specific bulk-cultured T cells established from seven HLA-B*51:01+
Japanese individuals chronically infected with HIV-1 by limiting dilution in
U-bottom 96-well microtiter plates (Nunc, Roskilde, Denmark). Each well
contained 200 ml cloning mixture (∼1 3 106 irradiated allogeneic PBMCs
from healthy donors and 1 3 105 irradiated C1R-B*51:01 cells prepulsed
with the corresponding peptide at 1 mM in RPMI 1640 supplemented with
10% human plasma and 200 U/ml human rIL-2).
TCR clonotype analysis
HLA-B*51:01–TI8 tetramers were generated as previously described (7).
CTL clones were stained with the tetramers, anti-CD8 mAb, and 7-amino-
actinomycin D (7-AAD), and then tetramer+CD8+7-AAD2 cells were sorted
by using an FACSAria I (BD Biosciences). The cryopreserved PBMCs from
four chronically HIV-1–infected HLA-B*51:01+ individuals were stained
with B51-TI8 tetramers, anti-CD8 mAb, and 7-AAD. HLA-B*51:01–TI8
tetramer+ CD8+ 7-AAD2 cells were sorted into 96-well plates (Bio-Rad) by
using an FACSAria I (BD Biosciences). For samples from sorted single
HLA-B*51:01–TI8-specific CD8+ T cells and CTL clones, unbiased iden-
tification of TCR ab-chain usage was assessed as previously described (8).
A modification to the protocol was applied by using illustra ExoStar
(GE Healthcare), which contains alkaline phosphatase and exonuclease 1 to
remove unincorporated primers and nucleotides from the amplification re-
action prior to subsequent steps. For bulk-sorted HLA-B*51:01–TI8-specific
CD8+ T cells, TCR genes were cloned with a Zero Blunt TOPO PCR cloning
kit (Invitrogen), and then several clones were sequenced. Sequencing was
done with a BigDye Terminator v3.1. cycle sequencing kit (Applied Bio-
systems) and analyzed by ABI 3500 and 3500xL Genetic Analyzer
(Applied Biosystems, Carlsbad, CA). All TCR genes are identified using the
ImMunoGeneTics database (http://www.imgt.org).
Protein expression and purification
The extracellular domains of 3B TCR a-chain (residues 1–207), 3B TCR
b-chain (residues 1–247), and B51 H chain (residues 1–248 6 a bio-
tinylation tag) were inserted into separate pGMT7 expression plasmids for
expression under the T7 promoter (9). b2-microglobulin (residues 1–247)
was similarly expressed. Competent Rosetta DE3 Escherichia coli cells were
used to produce proteins using 0.5 mM isopropyl b-D-thiogalactoside to
induce expression as described previously (9–11). Biotinylated pMHCI was
prepared as previously described (12). TCR sequences were engineered to
incorporate a nonnatural disulphide bond to aid heterodimerization (9, 13).
Surface plasmon resonance experiments
Surface plasmon resonance (SPR) equilibrium binding analysis was per-
formed using a BIAcore3000 (GE Healthcare Life Sciences) equipped with
a CM5 sensor chip as previously reported (12, 14, 15). HLA-A*02:01–
ALWGPDPAAA and HLA-B*35:01–VPLRPMTY were used as a negative
controls on flow cells 1 and 3 in three separate experiments. SPR equilibrium
analyses were carried out to determine the KD values for the TCR at 25˚C in
triplicate (representative data shown). For all experiments, ∼300 response
units pMHC was coupled to the CM5 sensor chip surface. The TCR was then
injected at concentrations ranging from 10 times above and 10 times below
the known KD of the interaction at 45 ml/min. The KD values were calculated
assuming 1:1 Langmuir binding (AB = B*ABMAX/[KD + B]), and the data
were analyzed using a global fit algorithm (BIAevaluation 3.1).
Crystallization, diffraction data collection, and model
refinement
All protein crystals were grown at 18˚C by vapor diffusion via the sitting
drop technique. A total of 200 nl 1:1 molar ratio TCR and pMHCI (10 mg/ml)
in crystallization buffer (10 mM TRIS [pH 8.1] and 10 mM NaCl) was
added to 200 nl reservoir solution. 3B–B51-TI8 crystals were grown in
0.2 M sodium sulfate, 0.1 M BisTris propane (pH 6.5), and 20% w/v PEG
3350 (16). Data were collected at 100 K at the Diamond Light Source
(Oxfordshire, U.K.). All datasets were collected at a wavelength of 0.976
A˚ using an ADSC Q315 CCD detector (Area Detector Systems Corpora-
tion). Reflection intensities were estimated with the XIA2 package (17),
and the data were scaled, reduced, and analyzed with SCALA and the
CCP4 package (18). Structures were solved with molecular replacement
using PHASER (19). Sequences were adjusted with COOT (20) and the
models refined with REFMAC5. Graphical representations were prepared
with PyMOL (21). Data reduction and refinement statistics are shown in
Table I. The reflection data and final model coordinates were deposited
with the Protein Data Bank database (http://www.rcsb.org) (Protein Data
Bank 4MJI).
Results
A public TRAV17/TRBV7-3–encoded TCR dominates responses
to B51-TI8
We first generated TI8-specific CTL clones from seven HLA-
B*51:01+HIV+ patients who responded to this epitope. The stain-
ing of representative clones by pMHC tetramer with this B51-TI8
epitope is shown in Supplemental Fig. 1. A total of 73 clones were
analyzed for their TCRa- and TCRb-chain sequences by previ-
ously described methodology (8). In patients KI-021, KI-127, KI-
250, and KI-391, only T cells expressing TCRs with TRAV17/
TRBV7-3 genes were detected (Fig. 1A). Patients KI-051 and KI-
112 generated CTL clones expressing TRAV17/TRBV7-3 TCRs,
but also expressed a further private B51-TI8–specific clonotype.
The remaining patient (KI-124) used a completely different TCR
made from the TRAV8-6 and TRBV27 genes. Thus, the TRAV17/
TRBV7-3 clonotype was exclusively or predominantly detected in
six out of seven individuals tested. Importantly, in five of these
patients (except KI-391), the TCRa-chain consisted of a TRAV17,
TRAJ22, and an identical CDR3 sequence: CATDDDSARQLTF.
Curiously, the TCRb-chain was encoded by a combination of the
TRBV7-3, TRBJ2-2, and TRBD2 genes, with CDR3 sequence
CASSLTGGELFF, in patients KI-021 and KI-051 (termed the 3B
TCR in this study), whereas the TRBJ1-4 and TRBD1 or D2 were
used in conjunction with TRBV7-3 in patients KI-112, KI-127,
and KI-250 to produce the CDR3 sequence CASSLTGGKLFF
(underlining indicates the only amino acid variation between these
differentially encoded chains). This convergent evolution suggests
that TCRs with this chain may have a strong selective advantage
in vivo. A further patient, KI-391, exclusively used a different
Table I. Summary of 3B–B51-TI8 cocomplex structure
3B–B51-TI8
Hydrogen bonds (#3.2 A˚) 14
Hydrogen bonds (#3.4 A˚) 4
Vdw (#3.5 A˚) 37
Vdw (#4 A˚) 101
Total contacts 156
No. of a-chain CDR1/CDR2/CDR3
contacts (#4 A˚)
28/19/46
No. of b-chain CDR1/CDR2/CDR3
contacts (#4 A˚)
9/41/13
Peptide contacts 33
MHC contacts 123
Crossing angle 43.3˚
BSA (TCR–MHC) (A˚2) 2041.2
BSA (TCR–peptide) (A˚2) 492.2
BSA (TCR–pMHC) (A˚2) 2533.4
Surface complementarity (TCR–MHC) 0.6675
Surface complementarity (TCR–peptide) 0.6675
Surface complementarity (TCR–pMHC) 0.647
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TCR made from a combination of the TRAV17/TRBJ5 and
TRBV7-3/TRBJ1-3 genes. Although the exact sequence of both
CDR3 loops differed in KI-391, these loops exhibited an identical
length to that seen in all of the other patients (Fig. 1A). In sum-
mary, six out of seven patients used the TRAV17/TRBV7-3 TCR
(three exclusively).
Examination of T cell clones, as above, could possibly introduce
bias due to the ability of only certain clonotypes to proliferate in
culture. To control for such potential distortion, we analyzed the
clonotype of ex vivo B51-TI8–specific CD8+ T cells from four
patients (KI-021, KI-051, KI-112, and KI-124) in whom we could
readily gain PBMC samples and sort populations of B51-TI8
tetramer+ CD8+ T cells directly ex vivo. The clonotype of bulk-
sorted B51-TI8–specific CD8+ T cells was analyzed for these four
patients (Fig. 1B). In accordance with the T cell clone data, only
T cells expressing TCRs with TRAV17/TRBV7-3 genes were
detected in KI-021. Moreover, TRAV17/TRBV7-3 clonotypes with
identical lengths of CDR3a and b loops were also predomi-
nantly detected in KI-051. In KI-112, only the TRAV29/DV5/
TRBV11-3 clonotype was detected (Fig. 1B), although this clo-
notype was only expressed in one of eight CTL clones (Fig. 1A).
Interestingly, only the TRAV8-6/TRBV27 clonotype was found
in all CTL clones (Fig. 1A) and in ex vivo bulk-sorted T cells
(Fig. 1B) from KI-124, but different TRAJ, TRBJ, and TRBD
were found between two different cell sources. We further per-
formed a single-cell TCR analysis for the samples from KI-021
and KI-051. Paired TCR usage data are shown in Fig. 1C. The
TRAV17/TRAJ22/TRBV7-3/TRBJ2-2 clonotype was detected in
22 out of 25 B51-TI8–specific CD8+ T cells sorted from KI-021
PBMCs and 8 out of the 18 CD8+ T cells sorted from KI-051
PBMCs. Interestingly, there was an amino acid difference (Asp-
Glu) at position 93 in CDR3a between KI-021 and KI-051 in ex
vivo samples but not in CTL clones. TCR analysis for the bulk-
cultured T cells from KI-051 used for CTL cloning demonstrated
the same TCR sequence as the CTL clones (data not shown),
indicating that CTLs carrying the TCR with Asp at position 93
were selected during in vitro stimulation. Thus, TRAV17/TRBV7-3
clonotype was also detected in ex vivo samples from at least two
LTNPs (KI-021 and KI-051). These results show that the majority
of B51-TI8–specific CTLs express a public TCR with type IV
FIGURE 1. Detection of B51-TI8–specific CTLs expressing public TCRs with the TRAV17/TRBV7-3 genes. (A) TCR ab-chain usage of B51-TI8–
specific CTL clones established from seven HLA-B*51:01+ individuals infected with HIV-1. (B) Bulk TCR sequence analysis of ex vivo HLA-B*51:01–
TI8 tetramer binding CD8+ T cell populations from four of the individuals shown in (A). (C) TCR analysis of sorted single cells of ex vivo tetramer binding
CD8+ T cells from two patients. TCRs with the TRAV17/TRBV7-3 genes are highlighted in blue. The conserved TCR CDR3a Arg97 residue is shown in
red.
The Journal of Immunology 3
 at Cardiff U
niv on M
arch 10, 2014
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
bias, consisting of a conserved TRBV or TRAV gene, TRBJ or
TRAJ gene usage, and only one or two residue differences within
the CDR3 loop in multiple individuals (22, 23). The public nature
of this TCR the dominance of TI8 responses in HLA-B*51:01+
individuals, and the better disease prognosis associated with this
allele combine to make the public response especially interesting.
The 3B TCR binds to B51-TI8 with very weak affinity
To explore the molecular mechanisms underlying the selective
T cell response to B51-TI8, we generated a soluble form of the
public TCR (3B) isolated from a CTL clone expressing the
TRAV17/TRBV7-3 genes and the common CDR3 loops we
detected in our clonotypic analysis (Fig. 1). The affinity of most
pathogen-specific TCR–pMHCI interaction lies in the region of
KD = 1–10 mM (24). We used SPR to determine the equilibrium
binding affinity of the 3B TCR for B51-TI8. The 3B TCR bound
to B51-TI8 with the weakest affinity ever measured for a patho-
genic epitope (24), KD 81.8 mM, with kinetics that were too
rapid to measure (Fig. 2A). This unusually weak affinity war-
ranted further structure examination of Ag recognition by the
public 3B TCR.
The 3B TCR engages B51-TI8 in classical orientation
We solved the structure of the 3B–B51-TI8 complex to gain an
atomic perspective on the molecular basis for the selection of
this public clonotype in response to B51-TI8. The complex was
solved to 2.99 A˚, and molecular replacement was successful only
in space group P1 with statistics consistent with the resolution
(Supplemental Table II). Overall, the 3B TCR bound canonically,
with the TCR CDRs contacting the pMHC surface (Fig. 2B) in
a diagonal docking geometry (43.4˚) (Fig. 2C) as previously re-
ported for other TCR–pMHC complexes (25). The 3B TCR
broadly contacted the MHC surface (123 total contacts with 22
different MHC residues) with only 33 contacts made between the
TCR and peptide (Table I). The contact interface between the 3B
TCR and B51-TI8 generated an overall buried surface area (BSA)
of 2041.2 A˚2 toward the higher end of the observed range for
natural TCR–pMHC interactions (25).
Interactions between the 3B TCR and the restriction triad
dominate MHC contacts
Previous structures of TCR–pMHC complexes have shown that
most TCRs use three conserved MHC contact points (positions 65,
69, and 155; the restriction triad) (26, 27). The 3B TCR made
a broad contact footprint with the MHC surface, contacting 22
different residues (Fig. 3A, 3B, Supplemental Table III). However,
of the 123 interactions between the 3B TCR and the MHC surface,
∼40% (49 contacts) were with the restriction triad residues (Gln65,
Thr69, and Gln155), including 6 out of 14 hydrogen bonds (Fig. 3C,
3D, Table I). Aside from the restriction triad positions, Arg62 (con-
tacting TCR a-chain Asp94 and Gln98), Gln72 (contacting TCR
b-chain Gln53, Thr55, and Gly56), and Gln152 (contacting TCR
a-chain Arg97 and b-chain Thr100) were the other important
MHC contact residues, making a further 24 Van der Waals (Vdw), 1
FIGURE 2. The 3B TCR binds to B51-TI8 with very weak affinity and
engages B51-TI8 in classical orientation. (A) 3B TCR binding to B51-TI8.
Ten serial dilutions of 3B TCR were measured in three separate experi-
ments (with different protein preparations). Representative data from
these experiments are plotted. The equilibrium binding constant (KD)
values were calculated using a nonlinear curve fit (y = [P1x]/P2 + x). Mean
plus SD values are shown. To calculate each response, 3B TCR was
also injected over a control sample (HLA-A*02:01 in complex with
ALWGPDPAAA peptide or HLA-B*35:01 in complex with VPLRPMTY
peptide) that was deducted from the experimental data. (B) Overall binding
mode of the 3B TCR (a-chain in green and b-chain in blue) interacting
with B51 (gray) TI8 (red sticks). (C) Position and crossing angle of the 3B
TCR CDR loops (CDR1a, red; 2a, green; 3a, blue; 1b, yellow; 2b, cyan;
3b, orange) over the B51 (gray surface)-TI8 (red sticks).
FIGURE 3. Interactions between the 3B TCR and the restriction triad
dominate MHC contacts. (A) Position of the 3B TCR (a in green spheres
and b in blue spheres) over the B51 a1 helix (residues contacted by the 3B
TCR on the B51 a1 helix shown in yellow surface). (B) Position of the 3B
TCR (a in green spheres and b in blue spheres) over the B51 a2 helix
(residues contacted by the 3B TCR on the B51 a2 helix shown in yellow
surface). (C) Contacts between the 3B TCR CDR2b loop and the MHCa1
domain including the restriction triad residues Q65 and T69. (D) Contacts
between the 3B TCR CDR1 and 2a loops and the MHCa2 domain in-
cluding the restriction triad residue Q155. These important stabilizing
interactions include a number of Vdw contacts (black dotted lines, 4 A˚
cutoff) and hydrogen bonds (red dotted lines, 3.4 A˚ cutoff) with the MHC
surface.
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salt-bridge, and 3 hydrogen bonds with the 3B TCR (Supplemental
Table III).
The TI8 peptide lacks the canonical central bulge
Previous pMHCI structures have shown that the central residues in
the peptide generally bulge out of the MHC binding groove me-
diating TCR contacts (25). The fixed anchors at the N and C
termini of the peptide and the closed conformation of the MHCI
groove force longer peptides to bulge further out of the groove to
accommodate the extra central peptide residues (26). Different
T cells have been shown to have a preference for peptides of
specific length, presumably dependent on the size of the peptide
bulge (28). The 3B–B51-TI8 complex solved in this study is the
first ever, to our knowledge, human TCR–pMHCI complex with
an 8-mer peptide. The TI8 peptide, being an 8-mer (the shortest
length reported for natural MHCI binding peptides) lacked any
prominent central bulge and was almost flat in the binding groove,
akin to MHC class II peptide presentation (29, 30) (Fig. 4A). The
consequences of this flat binding mode were 2-fold. First, the 3B
TCR made only 33 contacts with the peptide (Table I), fewer than
typically observed for other TCR-pMHCI structures (25). Usually
the number of peptide contacts account for ∼35% of total contacts
rather than the ∼25% as seen in this study. Second, the lack of
peptide bulge enabled the TCR to form a closer interaction with
the MHC surface, supported by the comparatively large BSA of
2041.2 A˚ observed for the TCR–MHC interface (Table I) (22).
These observations demonstrate how the length of the peptide can
govern pMHC interactions. For instance, a previously reported
TCR–pMHC structure with a superbulged 13-mer peptide showed
that the TCR perched on the extended peptide bulge and made
limited contacts with the MHC surface (26).
Peptide positions 4 and 7 are the main contact residues for the
3B TCR
The 3B TCR contacted six peptide residues in the B51-TI8
complex, with the TCRa-chain contacting peptide residues 3–6
and the TCRb-chain contacting peptide residues 7 and 8. Despite
this broad binding, a total of just 33 interactions were made with
the peptide (Fig. 4B) compared with 123 with the MHC, illus-
trating the MHC-centric nature of the 3B–B51-TI8 interface. The
side chains of peptide residues Thr4 and Ser7 were orientated up
out of the groove and made the vast majority of the contacts,
making all 5 of the hydrogen bonds and 17 of the 28 Vdw
interactions between the 3B TCR and the peptide (Fig. 4C). The
position of the 3B TCR during binding also demonstrated that,
even though there was an amino acid difference (Glu-Lys) at po-
sition 104 in CDR3b of TRAV17/TRBV7-3 TCR in KI-112, KI-
127, and KI-250, compared with that of the 3B TCR identified in
CTL from KI-021 and KI-051, these differences were away from
the binding interface of the TCR. Thus, assuming that these two
TCRs use a similar binding register, which is likely as they only
differ at one residue, they probably use the same molecular mech-
anism to engage B51-TI8. These data indicate that functionally
identical TRAV17/TRBV7-3TCRs were selected in five out of
seven HLA-B51:01+HIV+ patients.
A conserved binding motif explains public selection of
B51-TI8–specific TCRs
Although the interaction between the 3B TCR and B51-TI8 in-
volved .20 different TCR residues (Supplemental Table III),
TCR CDR3a residue Arg97 accounted for 3 out of 5 hydrogen
bonds and 9 out of 23 Vdw contacts with the peptide and 3 out of
13 hydrogen bonds and 9 out of 110 Vdw contacts with the MHC
surface (Fig. 4D). Arg97 made this contact network by fitting into
a pocket formed by the MHC a2-domain and the peptide back-
bone, akin to a ball-and-socket joint. Thus, Arg97 is likely to be an
important driving force in this otherwise weak TCR–pMHCI in-
teraction, acting as an anchor grasping onto both the peptide and
MHC. In support of this notion, Arg97 was conserved in the
CDR3a loops of all of the TRAV17/TRBV7-3 TCRs detected
(Fig. 1A), including from patient KI-391 that expressed a distinct
CDR3a loop and ex vivo B51-TI8–specific CD8+ T cells in KI-
051 (Fig. 1B, 1C). In addition to the dominant role for Arg97 in the
CDR3a loop, the 3B TCR used a very broad binding motif that
included the majority of residues in the TRAV17/TRBV7-3–
encoded CDR1 and 2 loops. This additional network of interactions
provided a stable binding platform, enabling Arg97 to perform its
central role and thereby explaining the conservation of this clono-
type. Only the combination of the TRAV17 and TRBV7-3 genes
encoded for the correct arrangement of residues capable of inter-
acting with B51-TI8 in this mode, probably explaining the pre-
dominance of such clonotypes in the B51-TI8 response.
Discussion
HLA-B*27, HLA-B*51, and HLA-B*57 are associated with better
control of HIV infection (3–5). Previous studies with HLA-B*27
and HLA-B*57 have identified residue identical public TCR
responses [defined as residue-identical receptors found across dif-
ferent individuals who share a common MHC (22, 31)] against HIV
(32–35). For example, public TCR clonotypes were detected in HLA-
B*27–restricted p24 Gag-derived KK10-specific (KRWIILGLNK;
residues 263–272) CTLs (32, 36). KK10-specific CTLs, character-
ized by TRBV4-3/TRBJ1-3 or TRBV6-5/TRBJ1-1 gene expression,
were found to be preferentially selected in vivo and shared between
individuals. CTLs expressing this public clonotype exhibited high
levels of TCR avidity and Ag sensitivity, enabling functional ad-
vantages and effective suppression of HIV-1 replication (32, 36).
We previously demonstrated that the magnitude of B51-TI8–
specific CD8+ T cells was significantly correlated to low plasma
viral load in chronically HIV-1–infected HLA-B*51:01+ Japanese
hemophiliacs (7). No correlation was found between the magnitude
of the CD8+ T cell response to three other dominant HLA-B51–
FIGURE 4. The TI8 peptide lacks the canonical central bulge. (A) Side
view of the TI8 peptide (red sticks) conformation demonstrating the lack of
a central peptide bulge. (B) Contacts between the 3B TCR (a in green
sticks and b in blue sticks) and the TI8 peptide (red sticks). (C) Contacts
between the 3B TCR (a in green sticks and b in blue sticks) and the
peptide residues P4T and P7S (red sticks) that represent the majority of
interactions between the TCR and peptide. (D) Contacts between the 3B
TCR CDR3a-chain residue Arg97 and the B51 surface (gray sticks) and the
TI8 peptide (red sticks). 3B TCR CDR3a-chain residue Arg97 interacts
with a pocket formed by B51-TI8 in a ball-and-socket–like manner enabling
a number of Vdw contacts (black dotted lines, 4A˚ cutoff) and hydrogen
bonds (red dotted lines, 3.4 A˚ cutoff) to form at the TCR–pMHC interface.
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restricted HIV-1 epitopes (7), suggesting that B51-TI8–specific
CD8+ T cells might play an important role in the control of viral
replication in these patients. In this study, we identified a public
CTL clonotype, expressing TRAV17/TRBV7-3 TCR genes, de-
ployed against the immunodominant B51-TI8 epitope. These data
indicate that even CTLs having weak TCR affinity could play
a central role in the control of HIV-1. The 3B–B51-TI8 structure,
which to our knowledge is the first TCR–pMHCI complex structure
with the B51 allele and first structure of a human 8-mer peptide
TCR–pMHC complex, demonstrated that the conformation of the
TI8 peptide was relatively flat compared with the classical prom-
inent central peptide bulge observed for most other pMHCIs. This
flat conformation enabled the 3B TCR to bind in an MHC-centric
manner, broadly contacting the residues that form the restriction
triad. Despite the broad binding mode, a conserved Arg at position
97 in the CDR3a loop dominated contacts and was central to
binding. Arg97 was also present in patients that used a TCR with a
different CDR3a loop, underscoring its central role in the interaction.
Garcia et al. (37) previously solved the crystal structure of the
mouse 2C TCR in complex with H-2Kb bound to the 8-mer self-
peptide, dEV8 (EQYKFYSV). Analogous to the 3B TCR inter-
action, the 2C TCR, in complex with H-2Kb-dEV8, showed weak
affinity (KD  84.1 mM) (38), and the crystal structure of the
TCR–pMHC complex revealed that 2C TCR bound in an MHC-
centric manner (37). Furthermore, the relative flatness of the TI8
peptide in the binding groove resembles the flat conformation
typically observed in pMHC class II (pMHCII) structures (29).
Like most TCR–pMHCII complexes, the 3B TCR bound rela-
tively weakly in comparison with the average TCR–pMHCI in-
teraction (24). The structures of the 3B and 2C TCRs suggest
a general MHC-centric mode of binding to relatively featureless
peptides. The relatively low affinities of 3B and 2C TCRs for their
cognate peptides make it tempting to speculate that high-affinity
TCRs specific for flatter pMHC landscapes might be deleted
during thymic selection because high-affinity MHC-centric TCR
binding may increase the potential for cross-reactivity with self.
Thus, the weak affinity of the 3B TCR may represent the best B51-
TI8 specificity that can escape thymic deletion.
In conclusion, the structure of the 3B TCR in complex with
B51-TI8 demonstrates the molecular basis for the selection of this
public CTL clonotype in HLA-B*51:01+HIV+ patients by revealing
that TCR residues involved in the majority of interactions with
the B51-TI8 surface were only encoded by the TRAV17/TRBV7-3
TCR genes. This contact network enabled the conserved Arg97
residue in the CDR3a loop to make optimal contacts with B51-
TI8 via a ball-and-socket–type interaction. It is also noteworthy
that this to our knowledge first ever human TCR–pMHCI struc-
ture with an 8-mer peptide, which binds flat within the MHC
groove to provide a relatively featureless landscape, showed
similarities to the 2C interaction with H-2Kb–dEV8 and TCR–
pMHCII complexes. All of these TCRs bind to their relatively
"vanilla" cognate ligands with weak affinity compared with TCRs
that bind to the contoured landscapes of bulging MHCI-restricted
foreign peptides of nine or more amino acids in length. We
therefore suggest that weak affinity might be a common feature of
TCR binding to flat peptides.
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